Login to Your Account



No Clash of the Titans

With Approvals Likely, Obesity Drugs Expected to Coexist

By Brian Orelli
BioWorld Insight Contributing Writer

Thursday, June 28, 2012
Following Arena Pharmaceuticals Inc.'s big win for obesity drug Belviq (lorcaserin), Vivus Inc.'s Qnexa (phentermine/topiramate) is next in line. And, with a positive recommendation from the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) that drug also looks like it will get past the FDA on its second attempt.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription